Wegovy (Semaglutide) 2.4mg/dose is a Canadian pharmaceutical grade GLP-1 receptor agonist provided in a prefilled injectable pen for precise, single-dose administration. It is widely used in research to study metabolic regulation, glucose homeostasis, and energy balance pathways.

This high-quality formulation delivers consistent dosage accuracy and stability for long-term experimental use, allowing researchers to evaluate the physiological effects of GLP-1 receptor activation on metabolic and appetite-related mechanisms.

The Details:

• Dosage: 2.4mg semaglutide per dose

• Form: Prefilled injection pen

• Quantity: Single-use pen, ready for controlled application

• Packaging: Sterile, tamper-evident pen in sealed packaging

• Source: Canadian pharmaceutical grade

Key Features of Wegovy 2.4mg:

• Metabolic Regulation Research: Supports studies on energy homeostasis and glucose signaling.

• GLP-1 Pathway Analysis: Enables examination of incretin-related receptor pathways.

• Dose Precision: Prefilled delivery system ensures reliable and reproducible dosing.

• Appetite and Energy Studies: Investigated for effects on satiety and caloric intake regulation.

• Pharmaceutical Authenticity: Canadian-produced and independently verified.